Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373685 · ClinicalTrials.gov registry record · Phase 4
GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 8,067
- Enrollment target
NCT00373685 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 8,067 participants.
The verdict
NCT00373685, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8,067 participants
- Enrollment target
Study Summary
This study investigates if Celebrex has a lower incident of Gastrointestinal Events than other NSAIDS in subjects with osteoarthritis.
Interventions
- DRUG Celecoxib
- DRUG Any commercially available NSAID with the indication for osteoarthritis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,067 participants |
| Start Date | 2006-10 |
| Est. Completion | 2010-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00373685
The ClinicalTrials.gov registry entry for NCT00373685 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 8,067 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Celecoxib is the first listed.
NCT00373685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00373685 about?
NCT00373685 is a clinical study titled "GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)". This study investigates if Celebrex has a lower incident of Gastrointestinal Events than other NSAIDS in subjects with osteoarthritis.
What is the current status of trial NCT00373685?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8,067 participants. The study started on 2006-10. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00373685?
The interventions under investigation include: Celecoxib (DRUG), Any commercially available NSAID with the indication for osteoarthritis (DRUG).
Who is sponsoring clinical trial NCT00373685?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.